AU2018248324B2 - Proteins for the treatment of epithelial barrier function disorders - Google Patents

Proteins for the treatment of epithelial barrier function disorders Download PDF

Info

Publication number
AU2018248324B2
AU2018248324B2 AU2018248324A AU2018248324A AU2018248324B2 AU 2018248324 B2 AU2018248324 B2 AU 2018248324B2 AU 2018248324 A AU2018248324 A AU 2018248324A AU 2018248324 A AU2018248324 A AU 2018248324A AU 2018248324 B2 AU2018248324 B2 AU 2018248324B2
Authority
AU
Australia
Prior art keywords
seq
amino acid
protein
acid sequence
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018248324A
Other languages
English (en)
Other versions
AU2018248324A1 (en
Inventor
Stefanie BANAS
Karim DABBAGH
Todd Zachary DESANTIS
Andrew Whitman GOODYEAR
Tarunmeet GUJRAL
Andrew Wonhee HAN
Ye Jin
Toshihiko Takeuchi
Michi Izumi WILLCOXON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genevive Inc
Original Assignee
Genevive Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genevive Inc filed Critical Genevive Inc
Publication of AU2018248324A1 publication Critical patent/AU2018248324A1/en
Application granted granted Critical
Publication of AU2018248324B2 publication Critical patent/AU2018248324B2/en
Priority to AU2023202844A priority Critical patent/AU2023202844A1/en
Assigned to GENEVIVE, INC. reassignment GENEVIVE, INC. Request for Assignment Assignors: SECOND GENOME, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Prostheses (AREA)
AU2018248324A 2017-04-07 2018-04-06 Proteins for the treatment of epithelial barrier function disorders Active AU2018248324B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023202844A AU2023202844A1 (en) 2017-04-07 2023-05-08 Proteins for the treatment of epithelial barrier function disorders

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762482963P 2017-04-07 2017-04-07
US62/482,963 2017-04-07
US201762607706P 2017-12-19 2017-12-19
US62/607,706 2017-12-19
US201762611334P 2017-12-28 2017-12-28
US62/611,334 2017-12-28
PCT/US2018/026447 WO2018187682A1 (en) 2017-04-07 2018-04-06 Proteins for the treatment of epithelial barrier function disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023202844A Division AU2023202844A1 (en) 2017-04-07 2023-05-08 Proteins for the treatment of epithelial barrier function disorders

Publications (2)

Publication Number Publication Date
AU2018248324A1 AU2018248324A1 (en) 2019-10-31
AU2018248324B2 true AU2018248324B2 (en) 2023-02-09

Family

ID=63710147

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018248324A Active AU2018248324B2 (en) 2017-04-07 2018-04-06 Proteins for the treatment of epithelial barrier function disorders
AU2023202844A Abandoned AU2023202844A1 (en) 2017-04-07 2023-05-08 Proteins for the treatment of epithelial barrier function disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023202844A Abandoned AU2023202844A1 (en) 2017-04-07 2023-05-08 Proteins for the treatment of epithelial barrier function disorders

Country Status (12)

Country Link
US (3) US10251933B2 (cg-RX-API-DMAC7.html)
EP (1) EP3606542A4 (cg-RX-API-DMAC7.html)
JP (2) JP7789303B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200003821A (cg-RX-API-DMAC7.html)
CN (1) CN110769844B (cg-RX-API-DMAC7.html)
AU (2) AU2018248324B2 (cg-RX-API-DMAC7.html)
CA (1) CA3059354A1 (cg-RX-API-DMAC7.html)
IL (1) IL269853A (cg-RX-API-DMAC7.html)
MX (2) MX393998B (cg-RX-API-DMAC7.html)
SG (1) SG11201909334TA (cg-RX-API-DMAC7.html)
TW (1) TWI797116B (cg-RX-API-DMAC7.html)
WO (1) WO2018187682A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10251933B2 (en) 2017-04-07 2019-04-09 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
US11666627B2 (en) 2017-04-07 2023-06-06 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
EP3773644A4 (en) * 2018-04-06 2021-06-02 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
JP2022512639A (ja) * 2018-10-09 2022-02-07 セカンド ゲノム インコーポレイテッド 上皮バリア機能障害の治療に有効なタンパク質を送達するためのラクトコッカス・ラクティス発現系
WO2021035129A1 (en) * 2019-08-21 2021-02-25 Astrazeneca Collaboration Ventures, Llc Use of brazikumab to treat crohn's disease
US11666629B2 (en) * 2020-01-10 2023-06-06 National Taipei University Of Technology Peptide interacting with toll-like receptor 2 and the composition comprising the same
CN113773364B (zh) * 2021-08-25 2023-04-28 无锡市儿童医院 小分子肽及其制备方法和应用
WO2024098026A2 (en) * 2022-11-04 2024-05-10 Mink Therapeutics, Inc. B-cell maturation antigen (bcma) chimeric antigen receptor invariant natural killer t cells and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160279177A1 (en) * 2011-10-07 2016-09-29 4D Pharma Research Limited Bacterium for use as a probiotic for nutritional and medical applications
WO2016203221A1 (en) * 2015-06-15 2016-12-22 4D Pharma Research Limited Compositions comprising bacterial strains

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5783415A (en) 1991-03-29 1998-07-21 Genentech, Inc. Method of producing an IL-8 receptor polypeptide
AR053579A1 (es) * 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
ES2568938T3 (es) 2009-04-28 2016-05-05 Vanderbilt University Composiciones y procedimientos de tratamiento de trastornos que implican apoptosis de células epiteliales
JP2014093482A (ja) 2012-11-06 2014-05-19 Toshiba Corp 固体撮像装置の製造方法および固体撮像装置
GB201306536D0 (en) * 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
WO2015014973A2 (en) * 2013-07-31 2015-02-05 Institut National De La Recherche Agronomique Use of specific glycoside phosphorylases for the implementation of phosphorolysis or reverse phosphorolysis reactions
US10251933B2 (en) 2017-04-07 2019-04-09 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
US11666627B2 (en) * 2017-04-07 2023-06-06 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
WO2018223051A1 (en) 2017-06-02 2018-12-06 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160279177A1 (en) * 2011-10-07 2016-09-29 4D Pharma Research Limited Bacterium for use as a probiotic for nutritional and medical applications
WO2016203221A1 (en) * 2015-06-15 2016-12-22 4D Pharma Research Limited Compositions comprising bacterial strains

Also Published As

Publication number Publication date
US20180289770A1 (en) 2018-10-11
US20200148728A1 (en) 2020-05-14
AU2018248324A1 (en) 2019-10-31
MX2019012051A (es) 2020-02-12
CN110769844A (zh) 2020-02-07
SG11201909334TA (en) 2019-11-28
WO2018187682A1 (en) 2018-10-11
MX2022008842A (es) 2022-08-02
TW201841649A (zh) 2018-12-01
JP2020516615A (ja) 2020-06-11
US20240066095A1 (en) 2024-02-29
EP3606542A1 (en) 2020-02-12
US10251933B2 (en) 2019-04-09
US11207376B2 (en) 2021-12-28
IL269853A (en) 2019-11-28
EP3606542A4 (en) 2021-01-20
JP2024037834A (ja) 2024-03-19
MX393998B (es) 2025-03-24
JP7789303B2 (ja) 2025-12-22
TWI797116B (zh) 2023-04-01
CN110769844B (zh) 2025-01-21
KR20230144097A (ko) 2023-10-13
AU2023202844A1 (en) 2023-07-06
CA3059354A1 (en) 2018-10-11
KR20200003821A (ko) 2020-01-10

Similar Documents

Publication Publication Date Title
AU2018248324B2 (en) Proteins for the treatment of epithelial barrier function disorders
US12168677B2 (en) Proteins for the treatment of epithelial barrier function disorders
US12186364B2 (en) Proteins for the treatment of epithelial barrier function disorders
US11505583B2 (en) Proteins for the treatment of epithelial barrier function disorders
US20210380994A1 (en) Lactococcus lactis expression system for delivering proteins efficacious for the treatment of epithelial barrier function disorders
US11666627B2 (en) Proteins for the treatment of epithelial barrier function disorders
US12371456B2 (en) Proteins for the treatment of epithelial barrier function disorders
WO2019213105A1 (en) Methods and compositions involving plantaricin ef (plnef)
KR102903277B1 (ko) 상피 장벽 기능 장애 치료용 단백질
US20210309984A1 (en) ChiA Enzyme
KR20230030649A (ko) 인간 il23 수용체에 결합하는 폴리펩타이드

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: GENEVIVE, INC.

Free format text: FORMER OWNER(S): SECOND GENOME, INC.